Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? (Q34182224)

31 July 2017

1 reference

title

Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? (English)

1 reference

31 July 2017

1 reference

1 reference

J M Nabholtz

1

1 reference

31 July 2017

K Tonkin

2

1 reference

31 July 2017

M Smylie

3

1 reference

31 July 2017

H J Au

4

1 reference

31 July 2017

M A Lindsay

5

1 reference

31 July 2017

J Mackey

6

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

1

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

187-206

1 reference

31 July 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

A phase I trial of taxol given by a 6-hour intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Taxol administered as a 120 hour infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Phase I trial of Taxotere: five-day schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.187

21 January 2018

Identifiers

DOI

10.1517/14656566.1.2.187

1 reference

31 July 2017

1 reference